Mounjaro and Low Mood: How to Decide What to Do Next

Is low mood a recognised side effect of Mounjaro?

Mounjaro's SmPC and Patient Information Leaflet list mood changes (including low mood and depressed mood) under side effects requiring medical attention, alongside a specific warning about thoughts of self-harm or suicide. That listing reflects a regulatory obligation to report signals seen during post-marketing surveillance, not necessarily a high-frequency event seen in pivotal trials. In SURMOUNT-1, the large randomised trial that informed Mounjaro's UK licence, psychiatric side effects were not among the commonly reported findings at any dose.

That distinction matters when you're trying to decide whether a low mood you're experiencing is related to the medicine. It means the connection is plausible and worth taking seriously, not that you should assume the worst, but also not dismiss it. The full side-effect picture for Mounjaro is broader than the GI effects that dominate early discussions, and mood sits in the category of things a prescriber needs to hear about.

Tirzepatide acts on two gut-hormone pathways (GIP and GLP-1 receptors) that have roles beyond appetite. If you want to understand whether Mounjaro can cause low mood and what the evidence actually shows, that resource sets out the research in detail. What a prescriber can tell you is whether your specific mental health history, any concurrent medicines, and the timing of mood changes create a pattern that needs acting on.

Three factors that shape how a prescriber reads 'low mood on Mounjaro'

The decision your prescriber is really making is: is this medicine, lifestyle change, weight loss itself, or something unrelated? All three can produce low mood, and they can overlap.

Rapid body-weight change is not emotionally neutral. Some people feel genuinely better as their weight falls; others go through an unsettled period, particularly if the physical transformation happens faster than their sense of self adjusts. Reduced calorie intake, changes in social eating, and fatigue from GI side effects in the early weeks can each press on mood independently. Tracking when the low mood started (relative to dose increases, to big weight milestones, to other life events) gives a prescriber useful data. If you'd like a fuller picture of managing side effects during treatment, that resource covers the practical steps in more detail.

Pre-existing depression or anxiety is a separate consideration. Mounjaro's prescribing guidance does not list depression as an absolute contraindication, but a prescriber will factor in your mental health history, current medications (some antidepressants interact with GLP-1 medicines, and oral contraceptives may be less reliably absorbed during the first four weeks of Mounjaro), and whether you have adequate support in place. Being open about this at consultation (and at every repeat review) is not a barrier to treatment; it's what makes treatment safer.

Dose timing matters too. Mood dips sometimes cluster in the day or two after the weekly injection, as the medicine's concentration peaks. Noting a pattern like that is worth mentioning, because it changes the clinical read considerably.

When to get medical help, and what 'promptly' actually means

The NHS guidance on tirzepatide is clear: tell your doctor or pharmacist if you experience mood changes, including persistent low mood or changes in how you feel about yourself. "Promptly" means before your next scheduled review if symptoms are mild and not escalating. It means the same day (via your GP, NHS 111, or A&E) if you have thoughts of harming yourself or others, or if low mood is severe enough to affect your ability to function.

You can also report unexpected side effects directly to the MHRA through the Yellow Card scheme, which helps regulators track patterns across the wider population using Mounjaro. This doesn't replace contacting a clinician, but it contributes to the post-market safety picture for a medicine that still carries a Black Triangle (▼) designation, meaning it's under additional monitoring.

Stopping Mounjaro abruptly without clinical input is not generally advisable. If a prescriber does decide the medicine should be paused or discontinued, there's a managed way to do that. Acting on your own, particularly if weight-related conditions are being treated alongside, risks other health consequences. The right call is always to raise the concern first.

How nume reviews mood concerns at every stage of treatment

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, not software, not a triage algorithm. Before treatment starts, your mental health history forms part of the clinical picture. Before each repeat, the prescriber considers how you've tolerated the current dose, including any mood changes you've reported through our aftercare team, who are available seven days a week. If a concern warrants pausing, adjusting, or stopping treatment, that's the prescriber's call to make, and they make it on clinical grounds, not on a policy timer.

Understanding how tirzepatide interacts with mood more broadly is an area of active clinical interest, and the picture will sharpen as real-world evidence accumulates. For now, the honest answer is: low mood on Mounjaro is possible, worth reporting, and something a prescriber can help you interpret. It's rarely a reason to stop treatment without discussion, and always a reason to start one. If you're considering whether Mounjaro is right for you, check your eligibility with our clinical team.